OpenAlex
PricingAboutJobs
Log inGet started
Author

Ran Qi

Institutions: Affiliated Hospital of Jining Medical University, Jining Medical University
Observed institutions: Hebei Medical University, Third Hospital of Hebei Medical University, Affiliated Hospital of Jining Medical University, Jining Medical University
ORCID: 0000-0001-5417-7790
Observed ORCID: 0000-0001-5417-7790
OpenAlex ID: A5010854129
The efficacy and safety of first‑line anti‑PD‑1/PD‑L1 immunotherapy for gastric esophageal cancer: A systematic review and meta‑analysis of phase III randomized controlled trials
2023 · Xiaoyang Duan, Huazhen Du, et al. · Experimental and Therapeutic Medicine · 4
PDF
Cost-Effectiveness of First-Line Atezolizumab versus Chemotherapy in Non-Small-Cell Lung Cancer Patients Ineligible for Platinum-Containing Regimens
2024 · Lan-Fang Li, Ran Qi, et al. · Risk Management and Healthcare Policy · 2
PDF
Anlotinib plus penpulimab versus sorafenib as first-line treatment for unresectable hepatocellular carcinoma: a cost-effectiveness analysis from the perspective of the Chinese healthcare system
2026 · Gengliang Bai, Haoyu Yang, et al. · Frontiers in Oncology
PDF
Cost-effectiveness analysis of sintilimab plus chemotherapy versus chemotherapy alone for the first-line treatment of advanced oesophageal squamous cell carcinoma
2022 · Ran Qi, Xuyang Nie, et al. · Research Square
PDF
Works count: 4
Citation count: 6
H-index: 2
I10-index:
Year
Topic
Type
OpenAlex
Nonprofit
Open DataOpen Data
Open Source
Product
Search
Compare
Pricing
Repositories
Unpaywall
Unsub
Developers
API docs
Data snapshot
Status
Source code
Organization
About
Team
Testimonials
Brand
Jobs
Community
Help center
Contact
Events
Blog
Mailing list
Supporters
Legal
Privacy
Accessibility
Terms